Acalabrutinib maleate is under clinical development by AstraZeneca and currently in Phase III for Follicular Lymphoma. According to GlobalData, Phase III drugs for Follicular Lymphoma have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Acalabrutinib maleate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Acalabrutinib maleate overview
Acalabrutinib maleate (Calquence) is an anti-neoplastic agent. It is formulated as hard gelatin capsules, tablets, coated tablets and film coated tablets for oral route of administration. Calquence is indicated for the treatment of of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, for the treatment of patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic leukaemia (SLL) either as initial therapy or subsequent therapy.. and also in combination with obinutuzumab or as a monotherapy is indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia. Calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.
Acalabrutinib is under development for the treatment of peanut food allergy, recurrent or refractory central nervous system lymphoma (CNSL), anti-MAG mediated neuropathy, multiple myeloma, hairy cell leukemia, graft-versus-host disease, primary, secondary central nervous system lymphoma and secondary diffuse large B-cell lymphoma (DLBCL), first line diffuse large B-cell lymphoma, relapsed or refractory small lymphocytic lymphoma, refractory or relapsed or untreated mantle cell lymphoma, marginal zone B-cell lymphoma, Waldenstrom macroglobulinemia, recurrent glioblastoma multiforme, follicular lymphoma, marginal zone lymphoma, B-cell lymphoproliferative disorder, splenic marginal zone lymphoma nodal marginal zone lymphoma and extranodal marginal zone lymphoma, epithelial ovarian cancer, follicular lymphoma and relapsed, refractory and untreated chronic lymphocytic leukemia, relapsed or refractory mantle cell lymphoma, primary mediastinal [thymic] large B-cell lymphoma (PMBCL) and other B-cell malignancies, coronavirus disease 2019 (COVID-19), primary and secondary central nervous system lymphoma. It was also under development for relapsed and refractory multiple myeloma, fallopian tube cancer, peritoneal cancer, metastatic bladder cancer, metastatic pancreatic cancer, metastatic squamous lung adenocarcinoma, rheumatoid arthritis, metastatic urothelial carcinoma, recurrent, metastatic, unresectable head and neck squamous cell carcinoma coronavirus disease 2019 (COVID-19), pneumonia and cytokine storm.
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly- owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of Acalabrutinib maleate’s drug-specific PTSR and LoA scores, buy the report here.